What is LL-37?
LL-37 is the only human cathelicidin: a 37-amino-acid host-defense peptide made by white blood cells and by the lining of the skin, gut and airways. As a treatment it has been tested only on the skin of chronic ulcers. A small 2014 trial was positive, but a 148-patient phase 2b trial missed its main healing goal.
Video overview · 3:07
LL-37 Peptide: Wound Healing, Infections and Immunity. What the Trials Show
What this natural antimicrobial peptide does in the body, why it can also drive inflammation, the leg-ulcer trials (including a 148-patient trial that missed its main goal), and its FDA, compounding and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
LL-37 is a natural peptide your own body makes to fight germs, and online it's sold for wound healing, infections, immunity and gut health. Unlike many peptides, it has been tested in people, as a treatment for leg ulcers. Here's what those trials found.
LL-37 is thirty-seven amino acids long, and it's the only human member of a family of germ-killing peptides called cathelicidins. White blood cells and the lining of your skin, gut and airways make it, and its production is linked to vitamin D.
LL-37 punches through the membranes of bacteria, and it also sends signals that steer inflammation and help skin close over a wound. But that signaling cuts both ways: in psoriasis it helps turn the body's own DNA into an immune trigger, and it's raised in rosacea.
In the lab, mice that couldn't make it got worse skin infections, and blocking it in human skin samples slowed wound closure. It also helped new blood vessels grow in animals. Its link to cancer is mixed: it fueled ovarian tumors in mice but helped protect against colon tumors.
Now the human trials, all on hard-to-heal skin ulcers. A 2014 trial in thirty-four people looked promising for two of three strengths. But the bigger 2021 trial, in one hundred forty-eight patients, missed its main goal: wounds fully closed in about a quarter of people, on LL-37 or placebo. A small 2023 diabetic foot ulcer trial saw better healing tissue, but no faster shrinking.
So LL-37 has been given to people, but only as a cream or gel on skin ulcers, for up to thirteen weeks, where it was well tolerated. No trial has tested it by injection, for infections inside the body, or for gut health.
LL-37 is not FDA approved. The FDA says it lacks enough safety information, and flags possible pro-tumor effects, immune reactions, impurities, and harm to male reproduction seen in animal studies. It's on the agenda for the FDA's next compounding advisory meeting. In sport, it's likely covered by the ban on unapproved substances.
Does LL-37 heal chronic wounds? Mixed: a small trial was positive, but the larger one missed its goal. Does it fight infections in people? Limited: in the one infected-ulcer trial, bacteria didn't drop significantly. Does it boost immunity? Not supported: it adjusts immune signals, and can drive inflammation. And gut health? Unknown: no human trials.
The bottom line: LL-37 is a real part of your immune defenses. As a treatment, it's only been tested on skin ulcers, where the biggest trial missed its goal, and its immune effects cut both ways. It isn't approved. For every study and source, see the LL-37 profile on PepsRadar dot com.
Biological role or research focus
Host-defense peptide and wound research.
A topical wound trial cannot establish the safety or effect of a systemic research product.
Role reference: LL-37, the only human member of the cathelicidin family (review) · Biochim Biophys Acta 2006 ↗
Names you may encounter
LL37 · LL 37 · cathelicidin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Host-defense peptide
- Main research area
- Wound-healing research
- Evidence featured
- Human phase 2b trial
- Source check
- October 4, 2026
Quick answers
- Is LL-37 FDA approved?
- No. No FDA-approved drug contains LL-37. Source ↗
- Is LL-37 safe?
- LL-37 is a human host-defense peptide. Skin-ulcer trials found it well tolerated, but FDA notes animal signals of harm to male reproduction and possible tumor promotion. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
- Is LL-37 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
- Has the FDA taken action over LL-37?
- Yes. Our records list 3 FDA actions naming it, most recently on April 15, 2026: FDA listed Cathelicidin (LL-37) among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| HEAL LL-37 (2021) | Human phase 2b trial | 148 people with hard-to-heal venous leg ulcers. |
| LL-37 · first topical ulcer trial (2014) | Human randomized trial | 34 people with hard-to-heal venous leg ulcers. |
| LL-37 cream · diabetic foot ulcers (2023) | Human randomized trial | 25 people with mildly infected diabetic foot ulcers (13 on LL-37, 12 on placebo). |
| Cathelicidin-deficient mice · skin infection (2001) | Animal study | Mice genetically lacking the mouse cathelicidin, compared with normal mice. |
| LL-37 · ovarian tumor model (2009) | Animal and laboratory study | Mouse ovarian cancer xenograft models and cell experiments. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human phase 2b trial · 2021
HEAL LL-37
Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.
- Population / model
- 148 people with hard-to-heal venous leg ulcers.
- Study design
- Topical LL-37 versus placebo, alongside compression therapy.
- Main finding
- The full study population showed no significant healing improvement. A post hoc subgroup with larger ulcers showed signals of benefit.
- Limits & context
- A subgroup found after the main analysis is hypothesis-generating. Topical tolerability cannot establish the safety of systemic injection or prove antimicrobial benefit for unrelated infections.
Human randomized trial · 2014
LL-37 · first topical ulcer trial
Did the early wound-healing signal persist in larger research?
- Population / model
- 34 people with hard-to-heal venous leg ulcers.
- Study design
- Placebo run-in, four-week double-blind treatment with three topical concentrations or placebo, and four-week follow-up.
- Main finding
- The lowest concentration had a significantly higher healing-rate constant than placebo (P=0.003); the middle comparison did not reach significance (P=0.088). The highest concentration showed no healing difference.
- How to read it
- Within-group wound reduction and a treatment-versus-placebo comparison answer different questions.
- Limits & context
- Small sample and short follow-up limit confidence. The later 148-person trial did not improve healing overall. These topical findings do not establish systemic antimicrobial efficacy or safe injectable use.
Human randomized trial · 2023
LL-37 cream · diabetic foot ulcers
Did LL-37 cream help mildly infected diabetic foot ulcers heal?
- Population / model
- 25 people with mildly infected diabetic foot ulcers (13 on LL-37, 12 on placebo).
- Study design
- Double-blind comparison of LL-37 cream with placebo over four weeks, measuring wound area, granulation tissue, inflammatory markers and bacterial counts.
- Main finding
- Granulation-tissue scores were better with LL-37. Wound-area reduction, inflammatory cytokines and bacterial colony counts did not differ significantly from placebo.
- Limits & context
- A very small, short single-country trial. Better granulation tissue is not the same as faster wound closure, and topical use says nothing about injected LL-37.
Animal study · 2001
Cathelicidin-deficient mice · skin infection
Does the body's own cathelicidin protect against skin infection?
- Population / model
- Mice genetically lacking the mouse cathelicidin, compared with normal mice.
- Study design
- Skin infection with group A Streptococcus.
- Main finding
- Mice that could not make cathelicidin developed more severe, invasive skin infections.
- Limits & context
- This shows the natural peptide matters for defense in mice; it does not show that adding LL-37 to a healthy person prevents or treats infection.
Source: Innate antimicrobial peptide protects the skin from invasive bacterial infection. ↗
Animal and laboratory study · 2009
LL-37 · ovarian tumor model
Can LL-37 influence tumor growth?
- Population / model
- Mouse ovarian cancer xenograft models and cell experiments.
- Study design
- Tumor growth with LL-37 present or blocked.
- Main finding
- LL-37 promoted ovarian tumor progression by recruiting supporting cells; blocking it reduced tumor growth.
- Limits & context
- Other work found the opposite in colon cancer models, so the effect depends on tissue and context. These are not human cancer data.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
15 registered studies name LL-37 as an intervention; 1 is recruiting or under way, 0 have not started recruiting yet, 12 completed and 2 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 15 listed studies.
Related records in our PubMed snapshot
Combinatorial therapy of LL-37 and ADSCs accelerates diabetic wound repair by orchestrating NRROS-mediated crosstalk between TGF-β/SMAD and hippo/TEAD1 axes. ↗
Cytokine · Issue date 2026 Nov · Not appraised
WITHDRAWN: Corrigendum to "Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the modulation of SIRT3-SOD2-NF-κB signaling pathway" [Int. Immunopharmacol. 129 (2024) 111636]. ↗
International immunopharmacology · Issue date 2026 Oct 15 · Not appraised
Corrigendum to "Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the modulation of SIRT3-SOD2-NF-κB signaling pathway" [Int. Immunopharmacol. 129 (2024) 111636]. ↗
International immunopharmacology · Issue date 2026 Oct 1 · Not appraised
Exposure to the antimicrobial peptides LL-37 and ATRA-1 induces a lipidome response in Staphylococcus aureus that alters membrane biophysical properties. ↗
Biochimica et biophysica acta. Biomembranes · Issue date 2026 Oct · Not appraised
Coordination chemistry and antimicrobial activity of LL-37, its C-terminal fragment, and a peptidomimetic analogue. ↗
Dalton transactions (Cambridge, England : 2003) · Issue date 2026 Sep 29 · Not appraised
Risks & interactions
LL-37 is a human host-defense peptide. Skin-ulcer trials found it well tolerated, but FDA notes animal signals of harm to male reproduction and possible tumor promotion.
Placebo-controlled trials of LL-37 applied to venous leg ulcers, and an open-label trial of an oral bacterial product carrying LL-37, reported no clear safety concerns. These do not answer the safety of injected LL-37.
Warning signs in animal or lab studies: Cancer, now or in the past
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Harms seen in animal or lab studies
- Nonclinical findings suggest harmful effects on male reproduction (FDA)
- Nonclinical findings suggest it can promote tumors in some tissues (FDA)
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · LL-37 for hard-to-heal venous leg ulcers: first trial (2014) ↗ · HEAL LL-37 phase 2b ulcer trial (2021) ↗ · Oral LL-37 against Omicron: randomized trial (2023) ↗
Safety evidence & remaining uncertainty
FDA highlights limited safety data and nonclinical concerns. A tolerable topical trial cannot answer the risks of systemic exposure.
Source: FDA · Peptide compounding safety concerns ↗
What FDA flagged
FDA says it lacks sufficient safety-related information on LL-37. It notes nonclinical signs of harm to male reproduction, possible tumor-promoting effects, a risk of immune reactions, and concerns about impurities.
Source: FDA · Bulk substances that may present significant safety risks ↗
FDA compounding review
FDA has listed cathelicidin (LL-37) among five substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027. No date had been set when this was checked. A committee vote is advice to FDA, and inclusion on the bulks list would not make it an approved drug.
Source: FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Cathelicidin LL-37". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
FDA actions
- FDA listed Cathelicidin (LL-37) among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Any committee vote is advisory. (2026-04-15) source
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing LL-37 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
- FDA warning letter to a clinic-based compounder (Guyer Institute) stating LL-37 had not been nominated for the 503A bulks list and could not be used under the 503A exemptions. (2021-11-10) source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
Online, LL-37 is marketed for wound healing, infections, immunity and gut health. The human evidence covers only topical treatment of chronic leg and diabetic foot ulcers, for up to 13 weeks. No trial has tested injected LL-37, infections inside the body, or gut conditions.
Source: HEAL LL-37 phase IIb trial · Wound Repair Regen 2021 ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
LL-37 is cut from a larger precursor, hCAP-18, and kills microbes largely by disrupting their membranes. It also binds bacterial endotoxin, steers inflammation, and helps skin close over a wound in laboratory models.
Its immune effects cut both ways. In psoriasis, LL-37 helps turn the body's own DNA into a trigger for interferon-producing immune cells, and abnormally processed cathelicidin is linked to rosacea. In mouse cancer models it promoted ovarian tumors but helped protect against colon tumors.
Source: LL-37, the only human member of the cathelicidin family (review) · Biochim Biophys Acta 2006 ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- A topical wound trial cannot establish the safety or effect of a systemic research product.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did the full wound trial show a benefit?
No significant overall healing benefit was found.
Why is the large-ulcer subgroup not conclusive?
It was a post hoc analysis. Such a finding should guide a new properly designed study rather than replace the main result.
Has LL-37 been tested in people?
Yes, but only as a cream or gel on chronic ulcers, in three published trials of 25 to 148 people. The largest did not improve healing overall.
Source: HEAL LL-37 phase IIb trial · Wound Repair Regen 2021 ↗
Does LL-37 "boost" immunity?
That claim is not supported. LL-37 adjusts immune signaling, and in some settings, such as psoriasis and rosacea, it can drive inflammation rather than calm it.
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Human topical wound trial · PMID 34687253 ↗
- LL-37 · first topical ulcer trial · 2014 ↗
- LL-37, the only human member of the cathelicidin family (review) · Biochim Biophys Acta 2006 ↗
- LL-37 and self-DNA in psoriasis · Nature 2007 ↗
- Cathelicidin in rosacea · Nat Med 2007 ↗
- Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. ↗
- Innate antimicrobial peptide protects the skin from invasive bacterial infection. ↗
- The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. ↗
- FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
Can peptides cause cancer? What drug labels, animal studies and case reports show
Some approved peptide drugs carry cancer warnings, some research peptides raise concerns from lab work, and a few case reports make headlines. What each kind of evidence can and can’t show.
Read the guide →RESEARCH FIELD GUIDE
Tissue repair peptides: which have actually been tested in people?
A roundup of popular tissue repair peptides and what has been tested in people: BPC-157's tiny human record, thymosin beta-4 eye and ulcer trials, GHK-Cu skin studies, TP-508 and LL-37 wound trials, plus FDA and WADA status.
Read the guide →

